ArticleFrontiers in oncology2026
Spontaneous regression of stage IV advanced diffuse large B-cell lymphoma in an person living with HIV: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HIV-associated diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy with poor outcomes despite combination antiretroviral therapy (cART). Spontaneous regression in advanced-stage disease is exceptionally rare. Case description: A 66-year-old male with stage IV, non-germinal center DLBCL involving the liver achieved complete radiographic resolution of multifocal hepatic lesions without cytotoxic therapy following cART initiation. Remission has been sustained for over 36 months. Effective viral suppression and CD4+ T-cell recovery (from 200 to 571 cells/μL) were temporally correlated with tumor regression. Conclusion: Spontaneous regression of stage IV diffuse large B-cell lymphoma (DLBCL) is exceedingly rare among individuals with HIV infection. This case underscores the critical role of immune reconstitution via cART in treating HIV-associated lymphoma. Therefore, it is recommended to initiate cART as early as possible in HIV-positive lymphoma patients to restore immune function, which can positively influence lymphoma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.